Lead Product(s) : IPH5201,Carboplatin,Durvalumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer
Details : IPH5201 is a blocking antibody targeting the CD39 immunosuppressive pathway combination with durvalumab (anti-PD-L1) and chemotherapy, in treatment-naïve patients with resectable early stage non-small cell lung cancer (NSCLC).
Product Name : IPH5201
Product Type : Antibody
Upfront Cash : Inapplicable
June 26, 2023
Lead Product(s) : IPH5201,Carboplatin,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IPH5201,Durvalumab,Oleclumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : AstraZeneca
Deal Size : $75.0 million
Deal Type : Collaboration
Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer
Details : IPH5201 is a blocking antibody targeting the CD39 immunosuppressive pathway. CD39 is an extracellular enzyme that is expressed in the tumor microenvironment, on both tumor infiltrating cells and stromal cells in several cancer types.
Product Name : IPH5201
Product Type : Antibody
Upfront Cash : $50.0 million
March 06, 2022
Lead Product(s) : IPH5201,Durvalumab,Oleclumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : AstraZeneca
Deal Size : $75.0 million
Deal Type : Collaboration
First patient dosed in IPH5201 Phase I clinical trial in advanced solid tumors
Details : Anti-CD39 monoclonal antibody, IPH5201, advances to first-in-human clinical trial; first molecule from Innate/AstraZeneca expanded collaboration progressing to the clinic.
Product Name : IPH5201
Product Type : Antibody
Upfront Cash : Inapplicable
October 03, 2020
Reset All
